Proqr Therapeutics Bv Stock Revenue
| PRQR Stock | USD 3.84 0.17 4.63% |
ProQR Therapeutics BV fundamentals help investors to digest information that contributes to ProQR Therapeutics' financial success or failures. It also enables traders to predict the movement of ProQR Stock. The fundamental analysis module provides a way to measure ProQR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ProQR Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 6.5 M | 6.8 M |
ProQR | Revenue |
ProQR Therapeutics BV Company Revenue Analysis
ProQR Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current ProQR Therapeutics Revenue | 6.51 M |
Most of ProQR Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ProQR Therapeutics BV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of ProQR
Projected quarterly revenue analysis of ProQR Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of ProQR Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in ProQR Therapeutics' stock price.
ProQR Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for ProQR Therapeutics is extremely important. It helps to project a fair market value of ProQR Stock properly, considering its historical fundamentals such as Revenue. Since ProQR Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ProQR Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ProQR Therapeutics' interrelated accounts and indicators.
| 0.56 | -0.13 | -0.38 | 0.05 | 0.36 | ||
| 0.56 | -0.34 | -0.54 | 0.83 | 0.5 | ||
| -0.13 | -0.34 | -0.25 | -0.34 | 0.6 | ||
| -0.38 | -0.54 | -0.25 | -0.3 | -0.78 | ||
| 0.05 | 0.83 | -0.34 | -0.3 | 0.29 | ||
| 0.36 | 0.5 | 0.6 | -0.78 | 0.29 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
ProQR Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, ProQR Therapeutics BV reported 6.51 M of revenue. This is 99.91% lower than that of the Biotechnology sector and 99.12% lower than that of the Health Care industry. The revenue for all United States stocks is 99.93% higher than that of the company.
ProQR Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ProQR Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ProQR Therapeutics could also be used in its relative valuation, which is a method of valuing ProQR Therapeutics by comparing valuation metrics of similar companies.ProQR Therapeutics is currently under evaluation in revenue category among its peers.
ProQR Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ProQR Therapeutics from analyzing ProQR Therapeutics' financial statements. These drivers represent accounts that assess ProQR Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ProQR Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 362.6M | 172.0M | 452.1M | 247.6M | 145.1M | 192.7M | |
| Enterprise Value | 264.2M | 130.5M | 324.9M | 174.7M | 45.9M | 43.6M |
ProQR Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ProQR Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ProQR Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
ProQR Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in ProQR Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ProQR Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ProQR Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 155.9 K | Franklin Street Advisors Inc. | 2024-09-30 | 150 K | Millennium Management Llc | 2024-06-30 | 148.4 K | Two Sigma Advisers, Llc | 2024-06-30 | 131.5 K | Boothbay Fund Management, Llc | 2024-09-30 | 106.7 K | Susquehanna International Group, Llp | 2024-06-30 | 96.1 K | Citadel Advisors Llc | 2024-09-30 | 87 K | Squarepoint Ops Llc | 2024-06-30 | 84.7 K | Bank Of America Corp | 2024-06-30 | 73.2 K | Privium Fund Management B.v. | 2024-09-30 | 5.6 M | Adage Capital Partners Gp Llc | 2024-06-30 | 3.6 M |
ProQR Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.30) % | ||||
| Operating Margin | (2.19) % | ||||
| Current Valuation | 330.64 M | ||||
| Shares Outstanding | 105.91 M | ||||
| Shares Owned By Insiders | 14.49 % | ||||
| Shares Owned By Institutions | 24.90 % | ||||
| Number Of Shares Shorted | 413.76 K | ||||
| Price To Earning | (1.97) X | ||||
| Price To Book | 15.41 X | ||||
| Price To Sales | 22.12 X | ||||
| Revenue | 6.51 M | ||||
| Gross Profit | 4.8 M | ||||
| EBITDA | (24.1 M) | ||||
| Net Income | (27.54 M) | ||||
| Cash And Equivalents | 156.4 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 19.73 M | ||||
| Debt To Equity | 0.70 % | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | 21.55 M | ||||
| Short Ratio | 0.12 X | ||||
| Earnings Per Share | (0.32) X | ||||
| Target Price | 7.4 | ||||
| Number Of Employees | 156 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 406.68 M | ||||
| Total Asset | 137.88 M | ||||
| Retained Earnings | (400.85 M) | ||||
| Working Capital | 86.78 M | ||||
| Current Asset | 97.77 M | ||||
| Current Liabilities | 5.49 M | ||||
| Net Asset | 137.88 M |
About ProQR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ProQR Therapeutics BV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProQR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProQR Therapeutics BV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ProQR Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with ProQR Stock
Moving against ProQR Stock
| 0.83 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.82 | HLN | Haleon plc | PairCorr |
| 0.77 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.74 | ELAN | Elanco Animal Health | PairCorr |
| 0.69 | ZTS | Zoetis Inc | PairCorr |
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.